BACK TO TOP
KSE100
173,150.41
-1303.52
(-0.75%)
KSE100PR
54,325.37
-408.97
(-0.75%)
ALLSHR
104,363.56
-607.69
(-0.58%)
KSE30
52,816.28
-382.25
(-0.72%)
KMI30
245,363.65
-1015.13
(-0.41%)
BKTI
49,278.66
-677.84
(-1.36%)
OGTI
34,757.87
609.42
(1.78%)
KMIALLSHR
67,373.39
-233.28
(-0.35%)
PSXDIV20
78,786.44
-433.94
(-0.55%)
UPP9
60,358.55
-567.28
(-0.93%)
NITPGI
45,048.82
-226.94
(-0.50%)
NBPPGI
48,968.54
-184.40
(-0.38%)
MZNPI
30,456.09
-187.89
(-0.61%)
JSMFI
45,250.34
-291.84
(-0.64%)
ACI
24,030.26
-192.17
(-0.79%)
JSGBKTI
70,418.55
-799.02
(-1.12%)
HBLTTI
18,025.65
16-02-2026
4.26
(0.02%)
MII30
22,365.30
-107.36
(-0.48%)
Liven Pharma Limited
PHARMACEUTICALS
Rs.45.85
-0.40
(-0.86%)
1D
1M
6M
YTD
1Y
3Y
5Y
^ As of Tue, Feb 17, 2026 3:35 PM
REG
DFC
CSF
ODL
Open
47.94
High
47.94
Low
45.15
Volume
53,603
CIRCUIT BREAKER
41.63 — 50.88
DAY RANGE
45.15 — 47.94
52-WEEK RANGE ^
43.65 — 136.99
Ask Price
0.00
Ask Volume
0
Bid Price
0.00
Bid Volume
0
LDCP
46.25
VAR
15.50
HAIRCUT
22.50
P/E Ratio (TTM) **
N/A
1-Year Change * ^
-64.77%
YTD Change * ^
-11.78%

No record found

No record found

No record found

Market data powered by capitalstake.com. Provided by PSX. ** Based on unconsolidated financials
  * Returns not adjusted for payouts
  ^The historical stock prices have been adjusted to reflect stock splits to ensure comparability over time.

Company Profile

BUSINESS DESCRIPTION

Liven Pharma Limited was incorporated in Pakistan as a private Limited Company on October 21, 1991 and was converted into a public limited company on April 30, 1992 under the Companies Ordinance, 1984 (Repealed with the enactment of the Companies Act, 2017). The principal activity of the Company is the manufacturing of pharmaceuticals and allied products.

KEY PEOPLE
Kashif Hussain SiddiquieCEO
Atif Hussain SiddiqiChairman
Muhammad SaeedCompany Secretary
ADDRESS

49-Km, Multan Road, Lahore

WEBSITE

www.liven-pharma.com

REGISTRAR

F.D. Registrar Services SMC (Pvt.) Ltd., 1705,17th Floor, Saima Trade Tower A, I.I. Chundrigar Road, Karachi

AUDITOR

M/s Reanda Haroon Zakaria Aamir Salman Rizwan & Company, Chartered Accountants

Fiscal Year End

June

Equity Profile

Market Cap (000's)
5,182,900.83
Shares
113,040,367
Free Float
13,956,055
Free Float
12.35%

Announcements

Financial Results
Board Meetings
Others
DateTitleDocument
Jan 2, 2026Financial results for the quarter ended September 30, 2025. View   PDF
Nov 6, 2025Financial Results Summary for Year ended 2025 View   PDF
Nov 6, 2025Financial Result For the Year Ended June 30, 2025 View   PDF
Aug 18, 2025Transmission of quarterly Report for the period ended March 31, 2025 View   PDF
May 27, 2025LIVEN | Liven Pharma Limited (Formerly: Landmark Spinning Industries Limited) Transmission of Quarterly Report for the Period Ended 2025-03-31 PDF
DateTitleDocument
Jan 1, 2026Extracts of resolution passed in the board of directors meeting of Liven Pharma Limited - December 30, 2025 View   PDF
Dec 26, 2025Board meeting for the consideration of Quarterly accounts for the period ended September 30, 2025 View   
Dec 22, 2025Board Meeting other than financial results View   PDF
Dec 8, 2025Certified True Copy of Passed/Adopted in the 34th Annual General Meeting of Liven Pharma Limited View   PDF
Nov 5, 2025Notice of Annual General Meeting for the year ended June 30, 2025 View   PDF
DateTitleDocument
Jan 20, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Jan 19, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Jan 19, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Jan 19, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   
Jan 19, 2026Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations View   

Financials

All numbers in thousands (000's) except EPS

Annual
Quarterly
2024202320222021
Sales
Profit after Taxation(11,178)(12,325)(14,289)(14,634)
EPS(0.92)(1.02)(1.18)(1.21)
Q2 2025Q1 2025Q3 2024Q2 2024
Sales17,12688,910
Profit after Taxation(9,491)147,588(2,532)(2,646)
EPS(0.10)12.17(0.21)(0.22)
Data powered by Capital Stake. To provide comparable data, information might have been standardized. The data presented may therefore differ from issuer's annual report and 'as reported' data should be obtained directly from the source issuer. See the Capital Stake Terms of Use.

Payouts

Financial Reports